Literature DB >> 21481176

Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(®) P) for severe congenital factor XIII deficiency: a prospective multicentre study.

M Dreyfus, D Barrois, J-Y Borg, S Claeyssens, M-F Torchet, B Arnuti, B Pautard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21481176     DOI： 10.1111/j.1538-7836.2011.04281.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

1.  Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data.

Authors:  Cristina Solomon; Wolfgang Korte; Dietmar Fries; Inna Pendrak; Christine Joch; Albrecht Gröner; Ingvild Birschmann
Journal:  Transfus Med Hemother       Date:  2016-08-03       Impact factor: 3.747

2.  Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®.

Authors:  Majid Naderi; Mehran Karimi; Maryam Sadat Hosseini; Es Hagh Moradi; Morteza Shamsizadeh; Akbar Dorgalaleh
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

3.  Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals.

Authors:  Andrea Beyerle; Cristina Solomon; Gerhard Dickneite; Eva Herzog
Journal:  Pharmacol Res Perspect       Date:  2016-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.